The stock market continued to perform well on Wednesday, sending the S&P 500 to within a point of a new all-time record closing high. The Dow remained stubbornly below 20,000, but major market benchmarks posted gains of around half a percent as the latest release of minutes from the Federal Reserve’s Open Market Committee meeting didn’t raise any alarms or reveal any big surprises from monetary policymakers.
Category: Medicine
Here’s Why Inotek Pharmaceuticals Corp. Is Being Obliterated
Shares are collapsing in early-morning trading on Tuesday, falling more than 68% as of 10:05 a.m EST after the company reported results from a phase 3 study that failed to meet its primary endpoint. announced top-line results of its MATrX-1 trial on Tuesday.
The reasons we don’t study gun violence the same way we study infections
Three decades ago, a pair of researchers wrote in one of the country’s leading medical journals about a common cause of death and injury in the United States that received very little federal funding. “A thorough review of research awards for 1983 failed to identify a single research project on the topic of firearm injuries,” the authors wrote after scouring a database of the research funded by the National Institutes of Health.
The reasons we don’t study gun violence the same way we study infections
Three decades ago, a pair of researchers wrote in one of the country’s leading medical journals about a common cause of death and injury in the United States that received very little federal funding. “A thorough review of research awards for 1983 failed to identify a single research project on the topic of firearm injuries,” the authors wrote after scouring a database of the research funded by the National Institutes of Health.
Analysts’ Actions — Medtronic, Nokia, Paccar, Verizon and More
AmerisourceBergen was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: ABC .
Kitty litter helps Wyoming bentonite past drilling slump
The market for a peculiar type of clay is looking up thanks to improved prospects for oil and gas drilling and to cat owners who use the stuff to soak up their pets’ business. Over 90 percent of all bentonite mined in the U.S. and almost half worldwide comes from beds of ancient volcanic ash in Wyoming.
Kitty litter helps Wyoming bentonite past drilling slump
The market for a peculiar type of clay is looking up thanks to improved prospects for oil and gas drilling and to cat owners who use the stuff to soak up their pets’ business. Over 90 percent of all bentonite mined in the U.S. and almost half worldwide comes from beds of ancient volcanic ash in Wyoming.
3 Myths About Marijuana Stocks
What do Hercules, Thor, centaurs, and marijuana stocks have in common? They’re all the subjects of myths. Most myths have at least a little bit of truth interspersed with a lot that is false.
Biotech Stocks: What to Watch in 2017
You probably didn’t like 2016 very much if you owned biotech stocks. Many biotech stocks, including some solid ones, performed dismally.
3 Troubled Companies and How to Play Them in the New Year
The share prices of Mylan, Sears and Endo International fell dramatically in 2016, and the companies face significant challenges ahead. On a day of light economic news, the three major indices fell slightly Friday.
Why ImmunoGen, Inc. Shares Rocketed Higher by 29%
Unfortunately, the reason for ImmunoGen’s surge higher remains a bit of a mystery. The closest thing to tangible news for ImmunoGen that would have the potential to move the company’s stock was a press release this past Wednesday, Dec. 28. The press release was a needed feather in the cap for lead drug candidate mirvetuximab soravtansine .
Why Cliffs Natural Resources, Groupon, and Alnylam Pharmaceuticals Slumped Today
Thursday was another sluggish day on Wall Street, with the Dow once again moving away from the 20,000 mark rather than toward it. Most major market benchmarks were down slightly on the day, as investors seemed content to coast into the end of the year as they wait to see whether things in 2017 will go as well as the recent stock market rally would suggest.
Will Spinraza Supercharge Biogen’s Top Line Next Year?
SMA is an inherited neurological disorder that results in progressive muscle wasting, impacting a person’s ability to move and even breathe. Although this disease is rare, with a U.S. incidence rate of 1 in 10,000 live births, it is the leading genetic cause of death in infants, and prior to Spinraza’s approval it lacked any form of effective pharmaceutical intervention.
What Happened in the Stock Market Today
Fitbit shares spiked 7% following a rare piece of encouraging news about the fitness device maker’s holiday sales trends. Its activity tracking software was the second most-popular download among free apps on Apple ‘s iTunes this past week, beating such heavyweights as Snapchat, YouTube, and Instagram.
Seattle Genetics Plunges After Drug Studies Halted on Deaths
Seattle Genetics Inc. plunged the most in five years after U.S. regulators halted several early-stage blood cancer studies following the deaths of four patients who suffered from liver damage. The Food and Drug Administration halted the trials testing Seattle Genetics’s acute myeloid leukemia, or AML, therapy, called SGN-CD33A.
3 Precision Medicine Stocks to Buy in January
The National Institutes of Health defines precision medicine as “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.” For several companies, this approach is already a reality — and it has created opportunities for investors.
The 3 Biggest Risks for Pfizer in 2017
Could the new year present better opportunities for the big pharma? Yes, but challenges remain. Here are three of Pfizer’s biggest risks in 2017.
Gloomy start to year of rooster as bird flu hits South Korea
The year of the rooster looks set for a gloomy start. Egg prices are soaring and new year’s festivals are being canceled as South Korea fights its worst bird flu outbreak in more than a month.
Kubota Pharmaceutical and SBI Holdings Plan Joint Venture
The companies sign a letter of intent to form a joint venture, with one its aims being to create and fund an entity to develop ophthalmology mobile healthcare apps. Kubota Pharmaceutical Holdings and financial services and asset management company SBI Holdings announced Monday plans to create a joint venture to organize and manage entities to target specific ophthalmic drugs and devices.
Will 2017 Be Gilead Sciences Inc.’s Worst Year Yet?
The biotech stock is down over 25% in 2016. Sales for hepatitis C virus drugs Harvoni and Sovaldi are dropping like a brick.
How to Get a Better Night’s Sleep
Most people know they need to eat right and exercise to be healthy. But what about sleep? We spend about one-third of our lives asleep, and sleep is essential to better health.
How Much Will Medicare Cost You in 2017?
Medicare covers more than 57 million Americans, providing the healthcare coverage they need. Every year, though, the cost of Medicare typically goes up, and the program passes through those increases to its participants in the form of higher premiums, deductibles, and other expenses.
What Happened in the Stock Market Today
Stocks rose on Friday ahead of a three-day weekend in observance of the holidays. The Dow Jones Industrial Average Biotech Synergy Pharmaceuticals, which specializes in gastrointestinal therapies, soared 22% after it announced positive clinical test results.
This Startup Will Sequence Your DNA, So You Can Contribute To Medical Research
The price to sequence the human genome has dropped from $100 million in 2001 to just a few thousand dollars today. It’s now cheap enough that some people are starting to get sequenced out of sheer curiosity about what they might uncover.
Merck’s Ebola Vaccine Found to Protect Against Deadly Virus
An experimental Ebola vaccine manufactured by Merck & Co. was found to be highly protective against the deadly virus, showing promise in the fight against future outbreaks after an earlier epidemic killed thousands and highlighted a shortage of weapons to battle the disease.
J&J’s Decision to Walk Away Set Stage for Renewed Actelion Talks
Johnson & Johnson’s willingness to walk away from talks to acquire Swiss biotechnology company Actelion Ltd. for about $28 billion is the very thing that got the two sides back to the negotiating table. This week, amid rising pressure from shareholders, Actelion surprised investors and re-entered negotiations with J&J, which signaled a willingness to raise its offer if granted exclusivity, said people familiar with the matter.
Actelion Enters Exclusive Takeover Discussions with J&J
Actelion said on Wednesday it has entered exclusive negotiations with U.S. healthcare company Johnson & Johnson regarding what the Swiss biotech company called a “possible strategic transaction”.
Impax Searches for a New CEO
Wilkinson steps down amid feds’ generic price fixing investigation. J. Kevin Buchi, who joined the board last month, tapped as interim CEO.
Women really are better doctors, study suggests
If male doctors were able to do as well as their female counterparts when treating elderly patients in the hospital, they could save 32,000 lives a year, according to a study of 1.5 million hospital visits. A month after patients were hospitalized, there was a small, but significant difference in the likelihood that they were still alive or had to be readmitted to the hospital depending on the gender of the doctor who cared for them, according to the study published in JAMA Internal Medicine .
Harvard Bioscience an ‘Asymmetrical Long Shot’
One of the best parts of writing for Real Money is all the great people I get to meet. I have made some great friends with fellow contributors and Real Money subscribers over the years, and I enjoy hearing from everyone who writes and comments on my articles.
Finally Getting Back to a Stock Picker’s Market
The bulls continue to chug away with better than 2 to 1 breadth, but momentum is slowing. There are only about 140 stocks hitting new 12-month highs, as buyers are less inclined to chase.
The Most Expensive Drugs of 2016
Prescription drug prices have gotten out of control for many Americans and many insurers. Some drugs cost as much as premium sports cars.
Yoga for Everyone
It’s time to roll out your yoga mat and discover the combination of physical and mental exercises that for thousands of years have hooked yoga practitioners around the globe. The beauty of yoga is that you don’t have to be a yogi or yogini to reap the benefits.
Better Buy: bluebird bio, Inc. vs. Kite Pharma
Several clinical-stage biotechs are developing therapies usingchimeric antigen receptor T cells . Two of them in particular have enjoyed some good news in 2016: bluebird bio .